Spevigo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of inflammatory skin diseases, advancement in monoclonal antibody development, regulatory approvals for orphan drugs, increased diagnosis of GPP cases, expansion of specialty dermatology care.

The growth in the forecast period can be attributed to increasing investment in biologics research, growing focus on personalized autoimmune treatments, expansion of clinical trials for neutrophilic diseases, rising awareness of rare dermatological conditions, increased adoption of advanced biologic therapies. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising focus on rare autoimmune disease treatments, growing investment in il-36 pathway research, expansion of precision dermatology solutions, enhanced clinical focus on flare prevention.

The rise in healthcare spending is expected to drive the growth of the Spevigo market. Healthcare spending, which includes expenditures on medical treatments, medications, and hospital care, is increasing due to factors such as aging populations, growing healthcare needs, advances in medical technology, and rising costs of services and medications. Higher healthcare spending improves access to advanced treatments like Spevigo by enhancing diagnostic capabilities, expanding treatment infrastructure, and supporting affordability through reimbursement policies. For instance, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, up from 0.9% growth in 2022. Therefore, rising healthcare spending is expected to drive the Spevigo market.

A key trend in the Spevigo market is the focus on expanding geographic reach to increase patient access and strengthen competitive positioning through strategic partnerships, regulatory approvals, and targeted marketing. Expanding market access ensures broader availability of the treatment and improved outcomes for patients in diverse regions. For example, in May 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval for Spevigo from the Central Drugs Standard Control Organization (CDSCO) in India. Spevigo (spesolimab) injection is the first treatment for generalized pustular psoriasis (GPP) flares in adults, targeting the interleukin-36 receptor to block the immune pathway involved in GPP. In the EFFISAYIL 1 Phase II trial, 54% of patients treated with Spevigo achieved pustule clearance within one week, compared to 6% with placebo, demonstrating its efficacy.

In July 2025, Boehringer Ingelheim partnered with LEO Pharma, a Denmark-based company, to commercialize and further develop Spevigo globally. This partnership aims to expand patient access, leverage LEO Pharma’s dermatology expertise, and explore new indications for IL-36-mediated skin diseases, further driving the growth of the Spevigo market.

Major companies operating in the spevigo market are C.H. Boehringer Sohn AG & Co. KG.

North America was the largest region in the spevigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spevigo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spevigo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the spevigo market by increasing costs of imported biologic manufacturing inputs, specialized reagents, cold-chain packaging materials, and precision drug delivery components. Pharmaceutical manufacturing hubs in North America and Europe are most affected due to reliance on globally sourced active ingredients and biologic processing equipment, while Asia-Pacific faces cost pressures related to export-oriented production. These tariffs are contributing to higher production costs and pricing pressures for specialty biologics. However, they are also encouraging localized biologic manufacturing, regional supply chain strengthening, and investments in domestic monoclonal antibody production infrastructure.

The spevigo market research report is one of a series of new reports that provides spevigo market statistics, including spevigo industry global market size, regional shares, competitors with a spevigo market share, detailed spevigo market segments, market trends and opportunities, and any further data you may need to thrive in the spevigo industry. This spevigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spevigo (spesolimab) is a monoclonal antibody therapy used to treat generalized pustular psoriasis (GPP), a rare and severe form of psoriasis. It works by inhibiting the interleukin-36 receptor, which plays a central role in the inflammation associated with GPP. Spevigo helps reduce symptoms and flare-ups, providing an effective treatment option for patients with moderate to severe GPP.

The primary indications for Spevigo are generalized pustular psoriasis (GPP) and potentially other neutrophilic skin diseases under investigation. GPP is characterized by widespread pustules on the skin, often accompanied by fever, chills, and systemic symptoms, and can be life-threatening if untreated. Treatment with Spevigo focuses on controlling flare-ups and managing symptoms to improve quality of life. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by pediatric, adult, and geriatric patients.

The spevigo market consists of sales of spevigo (spesolimab) injections and solutions. Values in this market are ‘factory gate’ values, representing the goods sold directly by manufacturers to downstream entities or end customers. This includes sales of therapies, related services, and distribution costs.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.